← Back to patent-cliff list
CNM-Au8
Tier C — Watch / tradeCNM-Au8
Clene Nanomedicine Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Multiple sclerosis, Amyotrophic lateral sclerosis, Relapsing-remitting multiple sclerosis, 视神经疾病, Demyelinating disease, Parkinson's disease
Regional status
US
Phase III
2020-07-30
EU
No progress
2015-04-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CNM-Au8?
Approved indications include: Multiple sclerosis, Amyotrophic lateral sclerosis, Relapsing-remitting multiple sclerosis, 视神经疾病, Demyelinating disease, Parkinson's disease.
When does the CNM-Au8 patent expire?
No public expiry year is available for CNM-Au8 yet; this page updates once verified.
How do I get a quote for CNM-Au8 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06